Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: Implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS)

By Jill | 18 March 2025

Bilal Bashira,b ∙ See Kwoka ∙ Anthony S. Wierzbickic ∙ Alan Jonesd ∙ Charlotte Dawsone ∙ Paul Downief,g ∙ Fiona Jenkinsonh∙ Hannah Delaneyi ∙ Michael Mansfieldj ∙ Dev Dattak ∙ Yee Teohl ∙ Paul Hamiltonm,n ∙ Natalie Forrestero ∙ Dawn O’Sullivanp ∙ Maryam Ferdousia ∙ Paul N. Durringtona ∙ Alaa AbdelRazikq ∙ Antonio Gallor,s ∙ Philippe Moulint ∙ Handrean Sorana,b Abstract Background and aims Prognosis and management differ between familial chylomicronaemia syndrome (FCS), a rare autosomal recessive disorder, and multifactorial chylomicronaemia syndrome (MCS) or severe mixed hyperlipidaemia. A clinical scoring tool to differentiate these conditions has been devised but not been validated in other populations. The objective of this study was to…

Read More

Current Dietary Practice in the Management of Adults with Familial Chylomicronaemia Syndrome

By Jill | 16 March 2025

A UK Expert Panel Opinion Piece Introduction Familial chylomicronaemia syndrome (FCS) is a rare autosomal recessive disorder with an estimated prevalence of 1–2 per million, which equates to 55–110 people in England.1, 2 FCS is characterised by severe fasting hypertriglyceridaemia (HTG), defined as triglyceride (TG) concentrations >10 mmol/L (885 mg/dL) by the European Atherosclerosis Society Consensus…

Read More